Tamsulosin Hydrochloride and Telavancin Hydrochloride

• Generic Name: tamsulosin
• Dosage Forms: n.a.
• Other Brand Names: Flomax

Reduction of urinary obstruction and relief of associated manifestations (e.g., hesitancy, terminal dribbling of urine, interrupted or weak stream, impaired size and force of stream, sensation of incomplete bladder emptying or straining) in hypertensive or normotensive patients with symptomatic BPH.

Although drug therapy usually is not as effective as surgical therapy, it may provide adequate symptomatic relief with fewer and less serious adverse effects compared with surgery.

May consider combined therapy with an α1-adrenergic blocker and 5α-reductase inhibitor for men with bothersome moderate to severe BPH and demonstrable prostatic enlargement. Has been more effective than therapy with either drug alone in preventing long-term BPH symptom progression. Men at risk for BPH progression are most likely to benefit from combination therapy.

Manufacturer states that tamsulosin should not be used for the treatment of hypertension.

• Generic Name: telavancin
• Dosage Forms: n.a.
• Other Brand Names: Vibativ

Treatment of nosocomial pneumonia, including hospital-acquired and ventilator-associated pneumonia, caused by susceptible Staphylococcus aureus (including methicillin-resistant S. aureus [MRSA; also known as oxacillin-resistant S. aureus or ORSA]).

If documented or presumed pathogens also include gram-negative or anaerobic bacteria, concomitant use of an anti-infective active against such bacteria may be clinically indicated.

Manufacturer states reserve telavancin for use when alternative treatments for hospital-acquired or ventilator-associated bacterial pneumonia not suitable.

Skin and Skin Structure Infections

Treatment of complicated skin and skin structure infections caused by susceptible S. aureus (including MRSA), Streptococcus pyogenes (group A β-hemolytic streptococci, GAS), S. agalactiae (group B streptococci, GBS), S. anginosus group (includes S. anginosus, S. intermedius, S. constellatus), or Enterococcus faecalis (vancomycin-susceptible strains only).

If documented or presumed pathogens also include gram-negative or anaerobic bacteria, concomitant use of an anti-infective active against such bacteria may be clinically indicated.